254
Participants
Start Date
November 14, 2022
Primary Completion Date
March 1, 2027
Study Completion Date
March 1, 2027
durvalumab
Visits will be completed at W0 (durvalumab in combination with chemotherapy initiation) and at regular visits approximately every 6 weeks during the induction period (durvalumab + PE) (W6 and W12), then every two months during the maintenance period (durvalumab alone) for the first year and every three months up to the end of follow-up or the final visit at M36.
Research Site, Saint-Quentin
Research Site, Marseille
Research Site, La Rochelle
Research Site, Dijon
Research Site, Évreux
Research Site, Nîmes
Research Site, Nîmes
Research Site, Toulouse
Research Site, Toulouse
Research Site, Bordeaux
Research Site, Saint-Grégoire
Research Site, Saint-Etienne
Research Site, Angers
Research Site, Nancy
Research Site, Vannes
Research Site, Valenciennes
Research Site, Clermont-Ferrand
Research Site, Pau
Research Site, Bayonne
Research Site, Villeurbanne
Research Site, Gleizé
Research Site, Epagny Metz-Tessy
Research Site, Paris
Research Site, Rouen
Research Site, Le Chesnay-Rocquencourt
Research Site, Toulon
Research Site, Avignon
Research Site, Avignon
Research Site, La Roche-sur-Yon
Research Site, Limoges
Research Site, Créteil
Research Site, Argenteuil
Research Site, Osny
Research Site, Rennes
Lead Sponsor
Kappa Santé
INDUSTRY
AstraZeneca
INDUSTRY